Olopatadine Hydrochloride API

Olopatadine Hydrochloride API is a high-purity, stable-processable active pharmaceutical ingredient (API) for treating allergies. Belonging to the second-generation H1 receptor antagonists, it possesses highly selective anti-allergic activity with low central nervous system sedation. As an active pharmaceutical ingredient, it plays a crucial role in formulations and is an important raw material for treating allergic conjunctivitis, seasonal or perennial allergic rhinitis, and other allergic reactions. Olopatadine achieves rapid relief of allergy symptoms by selectively blocking histamine H1 receptors and inhibiting mast cell degranulation and the release of inflammatory mediators.

Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.

Olopatadine has two principal pharmacological actions. First, it is a relatively selective histamine H₁ receptor antagonist, inhibiting histamine-mediated immediate allergic responses. Second, it inhibits histamine release from mast cells. Together, these actions provide the pharmacological basis for its use in allergic conjunctivitis and nasal allergy products. Product information also reports a lack of appreciable activity at the α-adrenergic, dopamine, and certain muscarinic receptors studied.

In research models, olopatadine can help distinguish the effects of blocking histamine signaling from those of reducing histamine release. Results depend on the cell model, stimulus, and test concentration; an in vitro finding should not be directly translated into a clinical onset or duration of action.

Olopatadine hydrochloride is used in ophthalmic solutions at different strengths. For example, a U.S. label indicates olopatadine 0.2% ophthalmic solution for ocular itching associated with allergic conjunctivitis. Products at other strengths and dosing frequencies also exist. API selection therefore involves more than achieving dissolution: developers must evaluate formulation pH, osmolality, buffer and preservative systems, container compatibility, assay, and degradation products throughout shelf life.

Olopatadine hydrochloride is also formulated as a nasal spray. One U.S. product label specifies 665 μg of olopatadine hydrochloride per spray, equivalent to 600 μg of olopatadine free base. Nasal product development must assess delivered dose per actuation, spray characteristics, formulation pH, nasal tolerability, and dose consistency during use. These properties depend on the API, formulation, and delivery device together.

Systemic exposure following ophthalmic and nasal administration should be assessed separately. Product information describes low systemic exposure after topical ocular administration, while nasal formulations have their own human pharmacokinetic and safety data.

Manufacturing research should establish a process-specific impurity profile for olopatadine hydrochloride. Potential areas of investigation include residual starting materials and intermediates, reaction by-products, Z/E geometric isomers, residual solvents, and degradation products formed during storage or formulation. The impurities requiring control and their limits must be determined from the actual synthetic route, toxicological qualification, and requirements of the intended regulatory market. ICH guidance provides a framework for reporting, identifying, and qualifying impurities in drug substances.

An analytical development program may include:

•  HPLC or UPLC: assay, related substances, and stability-indicating methods;
•  LC–MS: investigation of unknown impurities and degradation products;
•  NMR, IR, and mass spectrometry: confirmation of structure and salt identity;
•  GC: residual-solvent analysis;
•  XRPD, DSC/TGA, and hygroscopicity testing: evaluation of solid-state and processing properties where relevant.